Results of this study suggest that IDH inhibitors may have a dual benefit in AML treatment by blocking the proliferation of AML cells directly and disrupting the R-2HG-induced bone marrow niche indirectly. The gene discussed is IDH2; the disease is acute myeloid leukemia.